

**Disclaimer:**

*“The content of this Deliverable D2.3 represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.”*

## D2.3 Educational resources on registry operations during the pandemic

**Grant Agreement number:**

881553

**Project acronym:**

SAVDON

**Work Package number:**

WP1

**Periodic report: 1st**  **2<sup>nd</sup>**  **3<sup>rd</sup>**  **4<sup>th</sup>** **x**

**Period covered:**

from 01<sup>st</sup> January to 31<sup>st</sup> December 2021

**Organisation:**

**World Marrow Donor Association**

**(WMDA)**

**LEAR:**

Martine Schuit

**Project coordinator:**

Lydia Foeken

**Tel:**

0031 88 505 7900

**E-mail:**

lydia.foeken@wmda.info

**Organisation website address:**

www.wmda.info



Co-funded by  
the Health Programme  
of the European Union

## Table of Contents

1. Preface .....	3
2. Survey: Registry Operations during a pandemic .....	4
3. Virtual Membership Meetings.....	7
4. Webinars.....	11
5. Public webpages .....	13
6. Conclusion.....	15
Appendices .....	16
References.....	121

## 1. Preface

This report, as part of the 2021 work programme of the World Marrow Donor Association (WMDA) for the EU Third Health Programme (2014-2020), outlines all activity and tools provided by WMDA to support registries and cord blood banks (CBBs) during the continuing SARS-CoV-2-Pandemic in 2021.

The importance of the services described in this deliverable can all be related to WMDA's vision and mission statement<sup>1</sup>. WMDA strives that patients worldwide have equal access to high-quality cells for transplantation from donors whose rights and safety are protected. By ensuring that WMDA members can collaborate globally and by enabling that best practices are shared between members, both stem cell donors and patients benefit.

In 2020, when the pandemic started to affect stem cell donation and transplantation processes, the WMDA acted pro-actively and alert to minimise negative outcome for patients and prevent unnecessary risks for donors. The actions that were taken in that first year of the pandemic and all communication and tools for members can be found in chapter 5 of EU Deliverable 2.2, 2020<sup>2</sup>.

As the pandemic continued in 2021, WMDA kept offering information and means for members to keep their operations up and running throughout the year. Each chapter in this document focuses on a specific aspect of the support and educational resources WMDA provided. Some appendices have been added to give an overview of the materials that are available for WMDA members exclusively on the digital platform [Share](#). Other appendices have been added to enhance or clarify the information given in this report.




## 2. Survey: Registry Operations during a pandemic

In 2020 WMDA developed a survey to check the impact of the SARS-CoV-2-Pandemic on Registry Operations. A first survey was sent through WMDA’s regular newsletter, Stem Cell Matters (SCM) in June 2020<sup>3</sup> to gather input that was presented during the WMDA Virtual Membership Meetings on 23 June 2020 by Ann O’Leary, who was chair-elect of the Registries Working Group at the time.

The survey can be found in Appendix 1. The complete report with responses from all respondents (n=74) can be viewed [here](#). The graphic below is a screenshot from this report, giving insight in the support that was sought from higher authorities by WMDA members.

11. Did you access support from higher authorities nationally or internationally such as (tick boxes):




As a follow-up, a second survey was sent out in order to gain better insight in the impact of the continuing pandemic for transplant activity and registry operations worldwide. A comparison was made between the period from 1 March 2019 to 31 August 2019 and the period from 1 March 2020 to 31 August 2020. A first request to fill out his survey was sent out through SCM 65<sup>4</sup>, end of September 2020 and closed in February 2021.

This survey can be found in Appendix 2. The preliminary results were first presented by Dunia Jawdat, Member of the WMDA Board representing Pillar 2 Supporting Global Development, during a special Christmas webinar on 16 December 2020.<sup>5</sup>

The final results were presented during the WMDA Virtual Meetings on 23 March 2021 by Ann O’Leary, who is the chair of the Registries Working Group since 1 January 2021. The presentation has been added as Appendix 3.

The graph below shows the effect of the pandemic for international work-up requests and shipments. An overall decline is visible for 2020, where an increase was to be expected, based on the steady increase that was seen as a trend the years before<sup>6</sup>. Effects of the pandemic on import and export of hematopoietic stem cell products for EU Member States specifically are presented in Deliverable D2.1<sup>7</sup>.



As a result of the two surveys that were sent out in 2020, several WMDA members indicated their interest to look further into the subject of impact of the pandemic on registry operations, specifically in the change of amount of donations for bone marrow (BM) and peripheral blood stem cells (PBSC) pre-pandemic (2019) and during the pandemic (2020). The annual WMDA Global Trends Report<sup>8</sup> was used to determine the 10 patient countries/regions with largest absolute increase and the 10 countries/regions with largest absolute decrease in hematopoietic stem cell (HSC) donations (both BM and PBSC) in 2020 compared to 2019. The organisations in these 20 countries were specifically addressed for further analysis.



The results of the study will be presented orally (see screenshot of the pre-recorded presentation on the next page) and as a Poster Abstract<sup>9</sup> during the Annual meeting of the American Society of Hematology (ASH) on 13 December. Subsequently, a paper will be submitted to BMT Journal<sup>10</sup> in December 2021 for official publication.

## Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020

### Report from World Marrow Donor Association

Monique Jörjs<sup>1</sup>, Stefanie Bernas<sup>2</sup>, Alexander H. Schmidt<sup>3</sup>, Jay Feinberg<sup>3</sup>, Nicoletta Sacchi<sup>4</sup>, Heidi Elmoazzen<sup>5</sup>, Fatma Oguz<sup>6</sup>, Danielli Oliveira<sup>7</sup>, Kuo-Liang Yang<sup>8</sup>, Soraya Moomiwand<sup>9</sup>, Seied Asadullah Mousavi<sup>10</sup>, Helder Trindade<sup>11</sup>, Juliana Villa Lopez<sup>12</sup>, Mirjam Fechter<sup>13</sup>, Guidane Seval<sup>14</sup>, Cengiz<sup>15</sup>, Thaneya Jayarajah<sup>16</sup>, Steven Devine<sup>16</sup>, Bronwen E. Shaw<sup>16</sup>, Stephen J. Forman<sup>17</sup> and Lydia Foeken<sup>1</sup>

<sup>1</sup>WMDA, Leiden, Netherlands; <sup>2</sup>DKMS, Tuebingen, Germany; <sup>3</sup>Gift of Life, Boca Raton, FL; <sup>4</sup>BMDR - E.O. Galliera Hospitals, Genova, Italy; <sup>5</sup>Canadian Blood Services, Ottawa, Canada; <sup>6</sup>Blood and Bone Marrow Donor Registry of Istanbul Faculty of Medicine, Istanbul, Turkey; <sup>7</sup>Brazilian Bone Marrow Registry (REDOME), Instituto Nacional do Câncer, Ministério da Saúde, Rio de Janeiro, Brazil; <sup>8</sup>Buddhist Tzu Chi Stem Cells Center, Buddhist Tzu Chi University, Hualien, Taiwan; <sup>9</sup>Research Institute of Hematology Oncology and Cell Therapy, Iranian Stem Cell Donor Program, Tehran, Iran (Islamic Republic of); <sup>10</sup>CEDACE Portuguese BMD Registry, Lisbon, Portugal; <sup>11</sup>Registro de Donantes de Médula Ósea, Barcelona, Spain; <sup>12</sup>Matchis, Leiden, Netherlands; <sup>13</sup>Ankara University School of Medicine, Ankara, Turkey; <sup>14</sup>Anthony Nolan, London, United Kingdom; <sup>15</sup>National Marrow Donor Program, Minneapolis, MN; <sup>16</sup>CIEMAT, Medical College of Wisconsin, Milwaukee, WI; <sup>17</sup>Department of Hematology/HCT, City of Hope, Beckman Research Institute, Duarte, CA

The poster<sup>11</sup> is available online. Find a screenshot below:

## Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020

### Report from World Marrow Donor Association

Monique M. Jörjs (PhD)<sup>1</sup>, Stefanie N. Bernas (PhD)<sup>2</sup>, Alexander H. Schmidt (MD, PhD)<sup>3</sup>, Jay Feinberg<sup>3</sup>, Nicoletta Sacchi (PhD)<sup>4</sup>, Heidi Elmoazzen (PhD)<sup>5</sup>, Fatma Oguz (MD, PhD)<sup>6</sup>, Danielli Oliveira (MD)<sup>7</sup>, Kuo-Liang Yang (PhD)<sup>8</sup>, Seied Asadullah Mousavi (MD)<sup>9</sup>, Soraya Moomiwand<sup>9</sup>, Helder Trindade (MD, PhD)<sup>11</sup>, Juliana Villa Lopez (MD)<sup>12</sup>, Mirjam M. Fechter (MD)<sup>13</sup>, Guidane Seval (MD)<sup>14</sup>, Thaneya Jayarajah<sup>16</sup>, Steven M. Devine (MD)<sup>16</sup>, Bronwen E. Shaw (MD, PhD)<sup>16</sup>, Stephen J. Forman (MD)<sup>17</sup>, Lydia Foeken<sup>1</sup>

<sup>1</sup>World Marrow Donor Association, Leiden, the Netherlands; <sup>2</sup>DKMS, Tübingen, Germany; <sup>3</sup>Gift of Life Marrow Registry, Boca Raton, USA; <sup>4</sup>BMDR - E.O. Galliera, Genova, Italy; <sup>5</sup>Canadian Blood Services, Ottawa, Canada; <sup>6</sup>Blood and Bone Marrow Donor Registry of Istanbul Faculty of Medicine, Istanbul, Turkey; <sup>7</sup>REDOME, Rio de Janeiro, Brazil; <sup>8</sup>Buddhist Tzu Chi Stem Cells Center, Buddhist Tzu Chi University, Hualien, Taiwan; <sup>9</sup>Research Institute of Hematology Oncology and Cell Therapy, Iranian Stem Cell Donor Program, Tehran, Iran; <sup>10</sup>CEDACE Portuguese BMD Registry, Lisbon, Portugal; <sup>11</sup>Registro de Donantes de Médula Ósea, Barcelona, Spain; <sup>12</sup>Matchis, Leiden, the Netherlands; <sup>13</sup>Ankara University School of Medicine, Ankara, Turkey; <sup>14</sup>Anthony Nolan, London, UK; <sup>15</sup>National Marrow Donor Program/Be The Match, Minneapolis, MN, USA; <sup>16</sup>CIEMAT, Milwaukee, USA; <sup>17</sup>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA

Presenter  
8073425410148

#### INTRODUCTION

Because the COVID-19 pandemic had an impact on the treatment of patients with other diseases, we hypothesize that it also impacted the practice of unrelated hematopoietic stem cell transplantation.

#### METHODS

- We used the 2020 WMDA Global Trends Report to examine trends in unrelated hematopoietic stem cell (HSC) donations globally, per continent and per country/region.
- Donor registries and cord blood banks from 61 countries participated in 2020.
- We collected cumulative COVID-19 cases and deaths from December 31<sup>st</sup> 2020 and population data of 2020 per country/region.

#### DISCUSSION

- The decline in the number of unrelated HSC donations in 2020 suggests an impact of the COVID-19 pandemic.
- The decrease in BM collections and intercontinental/cross-border shipments can be explained by their logistically complex processes.
- Globally our data do not show the expected increased use of CBU suggesting that decisions to use CBU as a stem cell source did not change.
- We suspect the lack of correlation between country/region-specific severity of the pandemic and HSC donation numbers is due to COVID-19 data quality. Also, we did not gather monthly data and therefore could not specify pandemic waves.

#### RESULTS

- Total HSC donations from unrelated donors decreased to 19,623 (-3.5%) in 2020 (Figure 1).
- The 3.5% decrease is composed of a 29.0% decrease for bone marrow (BM) and a 2.6% increase for peripheral blood stem cells (PBSC).
- Globally, the number of cord blood unit (CBU) shipments decreased with 3.5%.
- National use of HSC products increased from 51.2% to 53.5% and HSC donations requiring intercontinental transport decreased from 24.6% to 21.9%.
- Considering the continent on which the patient is transplanted (table 1), the change rate of use of HSC products in 2020 vs. 2019 ranged from -28.0% in South America to +18.2% in Africa.
- The largest decrease of HSC donations occurred for patients in Asia (n=478) followed by Europe (n=205), and the largest increase occurred in North America (n=48) followed by Oceania (n=19).
- In terms of the country/region of transplant (table 2), the largest decrease occurred in Turkey (-147), with Japan following (-128), although Japan saw an increase of CBU use of +106).
- The greatest increase occurred in Italy (+67) and Netherlands (+66).
- The two countries receiving the largest HSC donation numbers showed no major changes versus the previous year: USA: +0.6% (although a decrease for CBU of -21.0% was observed) and Germany: -2.4%.
- We did not find any significant correlation between the numbers of COVID-19 cases or COVID-19-related deaths per 1 million inhabitants with the HSC donation numbers (Spearman's r=0.10 for cases and +0.13 for deaths).

In conclusion, we would like to point out that global exchanges of HSC products continued and only decreased slightly which is an extraordinary achievement of donor registries, cord blood banks and their donors and is a testament to the importance of international collaborations in WMDA.




Figure 1. Number of HSC donations from 2019 to 2020

Product	2019	2020	% Change
Bone Marrow (BM)	14,800	10,500	-29.0%
Peripheral Blood Stem Cells (PBSC)	4,200	4,300	+2.6%
Cord Blood Unit (CBU)	600	580	-3.5%
<b>Total</b>	<b>19,600</b>	<b>19,623</b>	<b>-3.5%</b>

Table 1. HSC donation per product type, 2019 vs. 2020. The continent on which the patient is transplanted. BM: Bone Marrow; PBSC: Peripheral Blood Stem Cells; CBU: cord blood unit; n (%): number of HSC; n (%): number of HSC requiring intercontinental transport.

Continent	2019	2020	% Change
Asia	10,500	9,022	-13.2%
Europe	4,200	4,095	-2.5%
North America	2,800	3,278	+17.1%
South America	1,200	870	-27.5%
Africa	800	950	+18.8%
Oceania	500	590	+18.0%
<b>Total</b>	<b>19,600</b>	<b>19,623</b>	<b>-3.5%</b>

Table 2. HSC donation per country/region, 2019 vs. 2020. The country/region of transplant. BM: Bone Marrow; PBSC: Peripheral Blood Stem Cells; CBU: cord blood unit; n (%): number of HSC; n (%): number of HSC requiring intercontinental transport.

Country/Region	2019	2020	% Change
USA	4,500	4,524	+0.5%
Germany	3,200	3,126	-2.3%
Italy	1,800	1,867	+3.7%
Turkey	1,200	1,053	-12.3%
Japan	1,000	872	-12.8%
UK	800	800	0.0%
France	700	700	0.0%
Spain	600	600	0.0%
Canada	500	500	0.0%
Australia	400	400	0.0%
Other	1,100	1,100	0.0%
<b>Total</b>	<b>19,600</b>	<b>19,623</b>	<b>-3.5%</b>

DISCUSSION

- Because of the impact of the COVID-19 pandemic on other diseases, we hypothesize that it also impacted the practice of unrelated hematopoietic stem cell transplantation.
- Our data do not show the expected increased use of CBU suggesting that decisions to use CBU as a stem cell source did not change.
- We suspect the lack of correlation between country/region-specific severity of the pandemic and HSC donation numbers is due to COVID-19 data quality. Also, we did not gather monthly data and therefore could not specify pandemic waves.

All HSC donation data taken from the WMDA 2019 and 2020 Global Trends Report, copies can be requested via [info@wmda.org](mailto:info@wmda.org). COVID data taken from Johns Hopkins University Center for Systems Science and Engineering <https://github.com/CSSEGISandData/COVID-19>. Population data taken from Worldometer website <https://www.worldometers.info/>.

### 3. Virtual Membership Meetings

In 2021 the WMDA organised two virtual events for the members to enable them to connect, collaborate and share best practices. The first event was held from 22 to 26 March. The program with links to the recordings has been added as Appendix 4.




**WMDA**  
**VIRTUAL**  
**MEETING WEEK**

**22-26 MARCH**  
**2021**

**WMDA**  
matching donors • serving patients

The WMDA virtual meeting week will be a celebration of innovation and will feature success stories of WMDA project groups..

WMDA has four pillars (see picture) and each day of the week was dedicated to a specific pillar. On Friday, 26 March, the Virtual Meeting Week was concluded with the General Membership Meeting.




The program provided opportunity for members to connect, share experiences and best practices and to collaborate on current topics. Presentations were given by working group representatives to share results of their work and there was also time for discussion and for meeting with the WMDA office staff to ask questions or learn more about WMDA and the services provided by the team.

Date	Topic	Unique Viewers <sup>?</sup>	Total Users <sup>?</sup>	Max Concurrent Views <sup>?</sup>
Mar 26, 2021	WMDA Virtual Meetings Week Daily Pillar Session	113	148	94
Mar 26, 2021	WMDA Virtual Meeting Week: Meeting Pearls	43	57	40
Mar 25, 2021	WMDA Virtual Webinar Week: Inspire&Connect - Cellular Therapy	66	91	69
Mar 25, 2021	WMDA Virtual Meetings Week: Table Talk - Couriers, sponsored by Overtime Courier	58	81	52
Mar 25, 2021	WMDA Virtual Meetings Week Daily Pillar Session	93	121	82
Mar 24, 2021	WMDA Virtual Meetings Week Daily Pillar Session	118	150	102
Mar 24, 2021	WMDA Virtual Meetings Week: WMDA insights - SEAR/SPEAR Annual report 2020	93	109	83
Mar 23, 2021	WMDA Virtual Meetings Week: Supporting Global Development - Cord Blood Banks	76	109	73
Mar 23, 2021	WMDA Virtual Meetings Week Daily Pillar Session	115	151	92
Mar 23, 2021	WMDA Virtual Meetings Week: Champions Ceremony - World Marrow Donor Day 2020	81	109	68
Mar 22, 2021	WMDA Virtual Meetings Week Daily Pillar Session	137	169	122
Mar 22, 2021	WMDA Virtual Meetings Week: The WMDA perspective on data security and privacy	79	96	75

The graph above, taken from the WMDA ZOOM account, gives information on the attendance of specifically the webinars that were given during the week. WMDA's YouTube channel shows that the various recordings were watched 652 times in total since they were uploaded end of March. This can be seen in the screenshots of all videos that have been added in Appendix 8.

A survey was sent out to attendees to ask for their feedback. WMDA received 36 responses, which have been added as Appendix 5.







In the second and third week of November 2021, the WMDA hosted the second series of Virtual Meetings. These were fully dedicated to the topic ‘Cellular Therapy’. The program with links to the recordings has been added as Appendix 6.

The aims that were set for these meetings were:

- *For members to better understand the importance of Cellular Therapy*
- *To clarify that Cellular Therapy can contribute to WMDA’s vision to ensure patients worldwide have access to high quality cells from donors whose rights and safety are protected*
- *For WMDA members to see involvement in Cellular Therapy as an opportunity and not as a risk or a threat*

One of the reasons to choose for this topic during the continuing pandemic has to do with the fact that more products are being discarded or remain cryopreserved due to the pandemic<sup>12</sup>. In the future these products might be put to good use for research and development of cellular therapies for the benefit of patients, which is aligned with WMDA’s vision to provide the best stem cell products for patients in need of a transplant.



The second virtual event was well-attended, as can be derived from the WMDA ZOOM account meetings' report:

Topic	Start Time	End Time	Duration (Minutes)	Participants
WMDA Virtual Meetings Cellular Therapy	11/08/2021 12:20:38 PM	11/08/2021 02:57:21 PM	157	<a href="#">148</a>
WMDA Virtual Meetings Cellular Therapy	11/09/2021 12:42:04 PM	11/09/2021 03:00:24 PM	139	<a href="#">159</a>
WMDA Junior Lab	11/10/2021 12:33:40 PM	11/10/2021 02:05:57 PM	93	<a href="#">42</a>
WMDA Virtual Meetings Cellular Therapy	11/15/2021 10:50:15 AM	11/15/2021 03:00:46 PM	251	<a href="#">132</a>
WMDA Virtual Meetings Cellular Therapy	11/16/2021 12:08:41 PM	11/16/2021 03:02:05 PM	174	<a href="#">149</a>
WMDA Virtual Meetings Cellular Therapy	11/17/2021 11:37:01 AM	11/17/2021 02:17:50 PM	161	<a href="#">213</a>

Only seven people gave feedback on the meetings, of which five rated the sessions with the highest score of 10 out of 10. The survey result has been added as Appendix 7.

Appendix 8 shows that the recordings have been viewed 196 times since they were uploaded in November.

## 4. Webinars

In 2021 12 educational webinars were given to support registry operations during the pandemic. This is the list of webinars that were given and the amount of people that attended, based on the statistics of the WMDA ZOOM Account:

Date	Topic	Live attendance
20211028	WMDA Webinar Series for Search Coordinators <a href="#">Related Donors</a> by Anne-Marie van Walraven	34
20211014	WMDA Warm-up Webinar for Virtual Meetings on Cellular Therapy <a href="#">Cellular Therapy Warm-up Webinar 2</a> by Julie Smolich and Steven Devine, NMDP-BeTheMatch	28
20210916	WMDA Warm-up Webinar for Virtual Meetings on Cellular Therapy <a href="#">Cellular Therapy Warm-up Webinar 1</a> by Daniel Gibson, Anthony Nolan	21
20210913	WMDA Meeting Security & Privacy Committee on Ransomware <a href="#">Ransomware</a> by Danny Attias, Jaap Dijkman, Hans-Peter Eberhard and Luke Neal	58
20210629	WMDA Webinar Series by the WMDA Communications Group <a href="#">Virtual Patient Appeals</a> by Amy Bartlett and Rowena Bentley	37
20210624	WMDA Webinar Series for Search Coordinators <a href="#">Perspectives in allogeneic search: Case Study</a> by Valerie Stewart	50
20210527	WMDA Webinar Series for Search Coordinators <a href="#">Challenges in the Asian-Pacific region</a> by William Hwang	34
20210422	WMDA Webinar Series for Search Coordinators <a href="#">HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation</a> by Effie Peterdorf	22
20210316	WMDA Webinar Series by the WMDA Communications Group <a href="#">Jumping Generations - Recruiting Gen Z</a> by Ryan Pena	36

Date	Topic	Live attendance
20210225	<i>WMDA Webinar Series for Search Coordinators</i> <a href="#">Recommendations for the selection of unrelated donors and cord blood units for allogeneic stem cell transplant</a>	71
20210128	<i>WMDA Webinar Series for Search Coordinators</i> <a href="#">Cord Blood Unit Selection: Shortlisting and detailed unit report analysis by Irina Evseeva, Laila Roberts and Roger Horton</a>	75
20210121	<i>WMDA Webinar Series by the WMDA Communications Group</i> <a href="#">Virtual Drives and other ways to manage Donor Recruitment during Covid 19 by Sabine Hildebrand</a>	33

Appendix 8 gives an overview of the screenshots of each webinar in chronological order with the amount of views since the webinar was posted until 7 December 2021, when the screenshots were taken.

## 5. Public webpages

Chapter 5 of the EU Deliverable D2.2 2020<sup>13</sup> describes the public webpages WMDA has been providing since the SARS-CoV2 pandemic started to affect international transportation and organisational operations. In 2021 one page was added to the WMDA Share Platform as a resource on the corona virus: ‘Vaccine programs/requirements and policies for donors’.

A link to this page is displayed on the public homepage of the Share Platform for online collaboration and knowledge sharing:

**Coronavirus- 2019-nCoV - COVID-19**

In the context of the coronavirus disease (COVID-19), WMDA has set up several information pages to provide you with an array of useful information and resources.

- [COVID-19 - Impact on Registry Operations](#)
- [Vaccine programs/requirements and policies for donors](#)
- [Courier information](#)

The analytics of the use of this page show that the page has been viewed by anonymous people 2.789 times since the page was launched on 14 January 2021. 55 Members have also visited this page once or more throughout the year.

Home Page / Registry policies on vaccine programs/requirements and policies for donors

### Content Analytics

Views Attachments



A screenshot of the page<sup>14</sup> has been added on the next page.

## Registry policies on vaccine programs/requirements and policies for donors

Created by Lydia Foeken, last modified on Sep 14, 2021

### Information for healthcare professionals:

- WMDA
- Czech National Marrow Donors Registry (ION-5440)
- Germany ZKRD (ION-6939)
- Italian Bone Marrow Registry (7450)
- Singapore Bone Marrow Donor Programme (ION-3785)
- Switzerland Swiss Registry for Blood Stem Cell Donors (ION-9341)
- United Kingdom
- United States of America NMDP-Be the Match (ION-3553)
- EBMT

### Important webpages:

[www.apheresis.org/page/covid](http://www.apheresis.org/page/covid)

### WMDA Foundation

#### WMDA

Click [here](#) for the COVID-19 vaccination guidelines developed by the Donor Medical Suitability Working Group.

### WMDA registries

#### Czech National Marrow Donors Registry (ION-5440)

CNMDR has adopted following preliminary policy for donors after vaccination against COVID:

- mRNA vaccines (Pfizer / BioNTech, Moderna) and protein vaccines (Novavax, Sanofi) – deferral of 7 days after each vaccination dose, provided no relevant side effects occurs.
- Vector vaccines (Astra Zeneca, Johnson & Johnson) – deferral of 28 days after each vaccination dose (a change of opinion after gaining more experience with vaccination cannot be ruled out).
- Information about the donor's vaccination sent to the transplant center

*With increasing experience the policy is likely to be modified.*

#### Germany ZKRD (ION-6939)

Germany does currently not have any specific regulation as far as SARS-CoV-2 vaccination and stem cell donation is concerned. The decision if a donor is eligible for PBSC donation after (any) vaccination is generally made by the collection center's physician. They will consider European (<https://www.ecdc.europa.eu/en/publicationsdata/coronavirus-disease-2019-covid-19-and-supply-substances-human-origin>) and WMDA (<https://share.wmda.info/display/DMSR/Vaccination>) recommendations in addition to German national guidelines, but decisions are made individually.

#### Israel Ezer Mizion Registry Israel Bone Marrow Donor Registry (ION-4987)

- Registry operational information available on: <https://share.wmda.info/x/hRNcAQ>; statement.
- **Update January 27:** please see [attachment](#) for a full update

#### Italian Bone Marrow Registry (7450)

IBMDR according to the Italian national requirements, applies this policy for COVID-19 Vaccination for Donors:

##### Deferral period after COVID-19 vaccination

- Donors (selected for TC/Work up and donation) and vaccinated with a vaccin based on weakened/ attenuated form of Sars -COV 2 -> deferral period of (at least) 4 weeks after each vaccin injection


The other corona pandemic related pages are still updated regularly, albeit not as frequently as in 2020, probably because changes of registry operation occur less often than in the first year of the pandemic.

The pages provide valuable information, based on the amount of views throughout the year:

### Space Analytics

Overview Content Users

DATE: 2021-01-01 - 2021-12-08 GROUP BY: Week DISPLAY: Total CONTENT: All



#### MOST POPULAR CONTENT

Welcome	1,398,215 views
COVID-19 - Impact on Registry Operations	10,513 views
Registry policies on vaccine programs/requirements and policies for donors	3,030 views
Courier information	1,701 views
Recently updated pages	785 views

#### MOST ACTIVE READERS



#### MOST ACTIVE CONTRIBUTORS



## 6. Conclusion

This was the final year of reporting for the EU Grant provided to WMDA. Thanks to this grant WMDA has been able to provide a lot of services for both members and non-members. The educational resources described in this deliverable will remain available indefinite (e.g. the recordings of webinars, mentioned in chapter 4), or for as long as needed (e.g. the information on SARS-CoV2 on Share, described in chapter 5).

Thank you to the European Union for their support throughout the past four years. It has contributed to the development of the World Marrow Donor Association immensely, which is not only a benefit for European stem cell donors and patients in need of a transplant, but also for all other donors and patients around the globe.

## Appendix 1.

### Registry Survey

**Short survey to present results at WMDA Virtual Meeting 2020 – Pillar 2, Global Development – to understand the immediate impact of COVID-19 on international registries**

---

Operations during the COVID-19 pandemic crisis to date ( 1 March 2020 to 31 May 2020):

1. What is the name of your registry?

2. What is your name?

**VALIDATION** %s format expected  
3. What is your e-mail address?



4. Did your registry stop all activity at any point?

- Yes - please describe when did it start, when did it end?

- No

5. Which, if any, of the following challenges have you faced due to COVID-19?

- Closing of your national borders, leading to issues with import / export
- Reduction in flights in and out of you country, leading to issues with import / export
- National restrictions / regulations on travel that impacted donors ability to travel to collection sites
- National restrictions / regulations on travel that impacted registry staff in getting to the registry office
- Increase in donor reluctance to donate due to the pandemic
- Increase in donor deferral for medical reasons (including COVID-19 diagnosis, exposure)
- Reduction in collection centre capacity for apheresis
- Reduction in collection centre capacity for bone marrow
- Other -Please share details of other specific challenges that your registry faced

6. Which, if any, of the following positive impacts have you experienced due to COVID-19?

- Increase in donor registration
- Increase in information requests about your organisation
- Publicity about your work during the pandemic
- Other - Please share details of other specific positive impacts that your registry has experienced

## 7. Which, if any, of the following changes have you implemented in your national registry

- Temporarily stopped the provision of blood samples for verification typing (providing a health and availability check only)
- Reduced the provision of blood samples for verification typing (eg. only providing samples where typing is low resolution or where CMV status is not known)
- Required transplant centers to cryopreserve cells and not begin patient conditioning until the cells are delivered
- Introduced a national transport hub(s) to ease imports / exports
- Introduced COVID-19 screening for national donors
- Introduced COVID-19 testing for national donors
- Added additional follow up with donors to proactively ask about COVID-19 symptoms post-donation
- Updated donor information to answer questions / provide reassurance about donation at this time
- Carried out COVID-19 risk assessments on each area of registry operations
- Increased use of international commercial / professional couriers
- Other - Please share details of other specific changes / solutions that your registry implemented to manage COVID-19

8. Which, if any, of the following social distancing measures did you introduce for your staff and / or donors?

- Introduced home-working for all or most registry staff
- Provided face-masks / gloves for staff who continued to travel to work
- Provided face-masks / gloves for anyone with direct contact with donors
- Provided face-masks / gloves for donors at physical exam and donation
- Made adjustments to your office / work space to allow for social distancing?
- Other - 6. Other – Please share details of other specific social distancing measures you introduced for you staff and / or donors?

9. Did your registry lose any products provided by your registry (ie. domestic provisions or exports) because of problems / delays during shipment (fresh or cryopreserved)? Yes / No

- No
- Yes, how many

10. Were any products provided by your registry (i.e. domestic provisions or exports) received but not used at the transplant center? Yes / No

- Yes - Please describe how many:

- No

11. Did your registry stop donor recruitment at any point:

- Face to face events?
- Online?

12. Did you access support from higher authorities nationally or internationally such as (tick boxes):

- National department of health
- National department of transport / customs / borders
- National competent authority
- National military
- Other - Please state:

**Cryopreservation**

---

13. During the COVID-19 pandemic crisis to date (1 March 2020 to 31 May 2020) can your national registry:

	Yes	No
Cryopreserve products collected nationally (at collection centre or other national location)?	<input type="radio"/>	<input type="radio"/>
Export fresh cells across your border?	<input type="radio"/>	<input type="radio"/>
Import fresh cells across your border?	<input type="radio"/>	<input type="radio"/>
Export cryopreserved cells across your border?	<input type="radio"/>	<input type="radio"/>
Import cryopreserved cells across your border?	<input type="radio"/>	<input type="radio"/>

14. Did the registry face any difficulties with cryopreservation?

Yes - Please state:

No

15. Once the COVID-19 pandemic crisis has passed, would your national registry consider continuing the cryopreservation of products for national patients (ie. domestic provision and imports)?

Yes

No

During the COVID-19 pandemic crisis to date (1 March 2020 to 31 May 2020) :

16. How many products have you provided?

	For national patients?	For international patients?
Bone Marrow	<input type="text"/>	<input type="text"/>
PBSC	<input type="text"/>	<input type="text"/>
Cord Blood	<input type="text"/>	<input type="text"/>

17. How many of the products have you provided have been cryopreserved?

	At collection centre	At transplant centre
March	<input type="text"/>	<input type="text"/>
April	<input type="text"/>	<input type="text"/>
May	<input type="text"/>	<input type="text"/>

**VALIDATION** Must be percentage

18. What % of your donors were unavailable at VT due to COVID-19 (eg. confirmed case, symptoms, exposure, fear)?

**VALIDATION** Must be percentage

19. What % of your donors were unavailable at workup due to COVID-19 (eg. confirmed case, symptoms, exposure, fear)?

20. Number of work-up postponements or donor cancelations due to COVID-19 (not considered a deviation), statistics or an estimation about the following reasons:

Positive tests: at PE/after DFC/during mobilization

Suggestive symptoms: at PE/after DFC/during mobilization

Need for quarantine: at PE/after DFC/during mobilization

Donor personal reason not to proceed to donation (e.g. fear to travel or visit a CC): at PE/after DFC/during mobilization



21. Please share with us any interesting stories or examples of specific issues your registry has faced during COVID-19  
Large free text comments box

**Thank You!**

---

Thank you for taking our survey. You are welcome to attend our virtual webinar on June 23 and learn from the experience from other registries.

## Registry operations during a pandemic - part 2

### General

---

**Page description:**

The WMDA Donor Registries WG worked on a second edition of the registry survey. The first edition was completed in June 2020 and results were shared at the WMDA virtual meetings in the same month.

As announced, we have developed a more in-depth survey to provide detailed data about the impact of COVID-19 on our activities to international organisations.

1. What is the name of your registry?

2. What is your name?

**VALIDATION** %s format expected  
3. What is your email address?

**LOGIC** Show/hide trigger exists.

#### 4. Did you ever use online donor recruitment before COVID-19?

- Yes
- No

**LOGIC** Hidden unless: #4 Question "Did you ever use online donor recruitment before COVID-19?" is one of the following answers ("No")

#### 5. Would you maintain online recruitment after the pandemic?

- Yes
- No

#### 6. Donor Recruitment Activity (face-to-face/public recruitment events)

	1 March 2019 to 31 August 2019	1 March 2020 to 31 August 2020
How many face-to-face / public recruitment events did you hold?	<input type="text"/>	<input type="text"/>
How many new potential donors were recruited via face-to-face recruitment events?	<input type="text"/>	<input type="text"/>
How many new potential donors were recruited online?	<input type="text"/>	<input type="text"/>

### Section 2 - Verification Typings

---

## 7. Donors for National Patients

	1 March 2019 to 31 August 2019	1 March 2020 to 31 August 2020
How many VT-requests were received for national patients?	<input type="text"/>	<input type="text"/>
How many of these VT-requests were fulfilled (i.e. blood samples provided)?	<input type="text"/>	<input type="text"/>
Of those NOT fulfilled, how many were provided: - A health and availability check	<input type="text"/>	<input type="text"/>
Of those NOT fulfilled, how many were provided: - Alternate samples / information (e.g. CMV status from swab)	<input type="text"/>	<input type="text"/>

## 8. Donors for International Patients

	1 March 2019 to 31 August 2019	1 March 2020 to 31 August 2020
How many VT-requests were received for international patients?	<input type="text"/>	<input type="text"/>
How many of these VT-requests were fulfilled (i.e. blood samples provided)?	<input type="text"/>	<input type="text"/>
Of those NOT fulfilled due to the pandemic, how many were provided: - A health and availability check	<input type="text"/>	<input type="text"/>
Of those NOT fulfilled due to the pandemic, how many were provided: - Alternate samples / information (e.g. CMV status from swab)	<input type="text"/>	<input type="text"/>

## 9. Donors for National Patients

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
How many adult donor workup requests were received for national patients?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

## 10. Of those workups, how many were:

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
Completed/shipped?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Active (e.g. scheduled/awaiting scheduling)?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
On hold or cancelled ?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

11. Of those completed/shipped, how many:

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
Were infused?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Are awaiting infusion?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Have been or will be discarded?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Remain cryopreserved until further notice?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

12. Donors for International Patients

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
How many adult donor workup requests were received for international patients?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

13. Of those workups, how many are now:

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
Completed/shipped?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Active (e.g. scheduled/awaiting scheduling)?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
On hold?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Cancelled?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

14. Of those completed/shipped, how many were shipped:

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
Fresh?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Cryopreserved at collection centre?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Cryopreserved after shipment?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

15. Of those completed/shipped, how many:

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
Were infused?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Are awaiting infusion?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Have been or will be discarded?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Remain cryopreserved until further notice?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

16. **Cord Blood Units shipped for National Patients**

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
How many cord blood unit request were received for national patients?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>



17. Of those requests, how many are now:

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
Completed/shipped?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Active (e.g. scheduled/awaiting scheduling)?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
On hold?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Cancelled?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

18. **Cord Blood Units shipped for International Patients**

	1 March 2019 to 31 May 2019	1 June 2019 to 31 August 2019	1 March 2020 to 31 May 2020	1 June 2020 to 31 August 2020
How many cord blood unit request were received for international patients?	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>





**24. Donor personal reason not to proceed to donation (e.g. fear to travel or visit a collection centre, lockdown or no travel possibilities for example closed borders between cities and no collection center in resident city of donor):**

	March	April	May	June	July	August
Before physical exam	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
At physical exam	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
After donor final clearance	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
During mobilization	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
On day of donation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**25. In case of collecting for a product that will be cryopreserved: when do donors get tested for COVID-19?**

- 1-2 weeks before collection
- 1-2 days before collection
- Not tested at all (if no symptoms or history or exposure)
- Other - Write In

**26. In case of collecting for a fresh product:** when do donors get tested for COVID-19?

- 1-2 weeks before collection
- 1-2 days before collection
- Not tested at all (if no symptoms or history or exposure)
- Other - Write In

### Section 5 - Donor Follow Up

---

**27. If your registry followed up with donors to ask about COVID-19 symptoms post-donation, during the period 1 March – 31 August 2020:**

How many donors were followed up?

How many donors reported symptoms?

Of those donors who reported symptoms, how many products were subsequently infused? - Transplant centre was informed after infusion.

Of those donors who reported symptoms, how many products were subsequently infused? - Transplant centre was informed before infusion.

### Thank You!

---

**Page description:**

Thank you on behalf of the Board Committee Global Development. We are aiming to present the results to you in October.

Thank you for taking our survey. Your response is very important to us.

# WMDA COVID-19 SURVEY

Results March 2021

Ann O'Leary

## Objective

- To understand the impact of COVID-19 on worldwide unrelated donation activity

## Methodology

- A survey to all WMDA members to compare activity from 1 March – 2020 to 31 Aug 2020 to the same period in 2019

# THANK YOU!

- 51 organisations from 42 countries responded
- Some challenges in question interpretation, so we have been validating.
- We are still working with 6 organisations to validate data
- All data compares Mar-Aug 2020 with Mar-Aug 2019
- Thanks to Monique Joris for collection, collation and analysis of the data

Republic of Korea  
Paraguay Brazil Taiwan Austria Armenia  
Spain United States South Africa Portugal Turkey Belgium Chile  
Canada Australia Italy Slovenia Israel Hong Kong Hungary Norway  
Saudi Arabia Ireland Singapore  
France Poland Serbia Japan Russian Federation China Thailand  
New Zealand Finland Czech Republic India Germany  
Uruguay United Kingdom Denmark Greece Switzerland  
Netherlands



# Impact on global donor recruitment

## March – August 2020 v March – August 2021

- Overall, 52% decrease in donor recruitment globally (representing more than 663k potential donors who would have been recruited during this period)
- Main impact on face-to-face recruitment, which was down 74%
- 16% decrease in online donor recruitment

# Impact on VTs

## March – August 2020 v March – August 2021

- VT requests during Mar – Aug 2020 were down 6% globally (but split between 1% increase for national patients and 15% decrease for international patients – with regional variation)
- Overall VT requests fulfilled were down by 31% (representing more than 11k samples)
- Alternative options were offered by some registries (e.g. health and availability checks; local typing with swap samples) and these options were used 8,700 times

## Impact on workups


March – August 2020 v March – August 2021

- For national patients, workup requests increased by 9% and workups shipped increase by 3%
- For international patients, workup requests decreased by 9% and workups shipped decreased by 14%
- Globally, there was a decrease in workups shipped of 6% (509 provisions) for Mar – August 2020, with the biggest impact on international provisions in March to May (9% decrease in workups shipped)

# Impact on workups

## March – August 2020 v March – August 2021

Products discarded or on hold  
March-August 2019 v 2020



## Impact on workups

March – August 2020 v March – August 2021

- Cancellations for national donors and CBU were increased mainly in March/May 2020 compared to 2019, this stabilised in the second period (June/August)
- Cancellations for international donors and CBU actually decreased (in donors only slightly, but significantly for CBUs) overall



# NEXT STEP



Final validation and confirmed data analysis

# Covid-19 Pandemic

## What did REDOME change in operations ?


Danielli Oliveira, MD, PhD





# Initial Considerations

- REDOME
  - Part of Brazilian Public Health System – limited autonomy
- Brazil – Continental dimensions
  - unequal distribution of health services (DC, CC, TC)
  - heterogeneity on circulation restrictions (lockdown)
- Economic impact of pandemic
  - Public funded Registry – risk of budget restrictions
  - Costs of international procedures (R\$ x US\$)



# Life in Isolation

- REDOME team started homeoffice on March 2020
  - 4 workers infected by Covid-19
  - Positive balance about homeoffice
- Donors can't donate from home
  - Review WU process – CT + WU simultaneously, decrease interval between medical appointments
  - Constant review of logistics for donors
  - In spite of the efforts, around 60% of donors had to travel for WU and collection

# Closed Border

- Support of Brazilian authorities to assure the arrival of courier – authorization from Ministry of Justice and Federal Health Agency (ANVISA)
- Review of itineraries
  - Use of international + national courier
- Essential role of courier companies
  - availability and commitment – partnership
  - extended time for PCR testing of international couriers

# Safety

- Communication as a essential strategy to promote safety



Development of a hot site at REDOME website directed to donors



Creation of a newsletter directed to the network


- Letter directed to donors during WU, explaining the preventive measures adopted by REDOME (but not excluding the risks)
- Donors' medical evaluation (by phone) before HSC collection
- Review of forms including questions directed to Covid-19 pandemic
- Discussion of protocols with Ministry of Health and medical entities - controversial
  - SARS-Cov-2 PCR testing at WU and pre-collection
  - Product quarantine

**12 cases of SARS-Cov-2  
positive donors**

# The new normal


- Cryopreservation
  - 55% REDOME donations
  - 70% international donations
  - Non-infused products ?

Cryopreserved products from REDOME donors  
(n=87, March-December 2020)



■ infused ■ scheduled ■ deceased patients

Cryopreserved products from international donors  
(n=66, March - December 2020)



■ infused ■ scheduled ■ deceased patients

# Time of Crisis – Opportunity ?

- 30% Reduction on URD transplant activity
- Review of internal processes – optimization
- Improvement of communication resources
  - Website updating
  - App for donor recruitment (pre-registration)
- Project – donor medical evaluation by telemedicine




# Suffering – Resilience

- “Celebration” of WMDD in order to reinforce the essential role of REDOME
- Optimistic perspective
  - REDOME team
  - REDOME network – DC, CC, TC, HLA labs

# Future

- Many uncertainties about the future – new lockdown from March 26
- **One belief about the future**






THANK YOU

# Challenges and Solutions to operate a registry during the pandemic.

Presented by – Sumati Misra (DATRI)

# Donors Registered




**0.426 Million**

Donors registered till 2019

WMDA Virtual Meetings Week 2021

# Number of Collections



**487** till 2019

WMDA Virtual Meetings Week 2021



WMDA Virtual Meetings Week 2021

## Comparison

- India should be seen not as a country but as a subcontinent
- Based on population and area, many countries are as big/small as states within India
- Managing the extreme complexity of a nation with a HUGE population, especially during the COVID pandemic





# COVID Vs DATRI



Family & other influencers don't want Donor to visit Hospital



Multiple Checking points

Permission E-pass from EACH State

GOVERNMENT OF KARNATAKA

**COVID e-Pass** No.:XXXXXXX

Name of Company: XYZ Foods  
 Name of Pass Holder: XXXXXX  
 Associated with: NA  
 Mobile Number: +91 88XXXXXXX  
 Nature of Work: XXXXXX  
 Valid Till: 24/04/2020  
 Valid for Locations: Bangalore





No Public and restricted Private Transport



Travel Restrictions

# COVID Vs DATRI .... Contd



**Long Travel duration for road transport**




**Colleges Shut down, Work from home ! – Donors relocate to their Native cities**



**Elective surgery on hold at Hospitals**

**What to do & How to reach our intended audience ?**





# Collections in April... Future ???

DON'T BE THE SAME.  
BE BETTER!



# Modification @ DATRI .....



IDMs



WMDA Virtual Meetings Week 2021

Donor Clearance




Online Consultations



# Some Solutions



Online DRMs



COVID test for donor  
**THRICE** before  
collection



Local Point to Point  
Courier



Kits for Donors



Safety Kits to staff

# Guidelines for Various Scenarios

DONOR	IDEAL DONOR	SYMPTOMATIC DONOR	CONTACT HISTORY WITH COVID (+) ve PERSON	COVID-19 TEST POSITIVE DONOR	COVID-19 TEST POSITIVE ON DAY 4 MOBILISATION
SYMPTOMS	NO	YES	NO / YES	NO	NO
CONTACT HISTORY WITH COVID (+) ve person	NO	NO	YES	NO	NO
DEFERRAL FOR PSC DONATION	NO	YES	YES	YES	YES
DEFERRAL FOR HOW MANY DAYS	NA	14	28	3 MONTHS	3 MONTHS
ASYMPTOMATIC FOR 14 DAYS	NA	YES	YES	NA	NA
COVID-19 TEST TO BE NEGATIVE ONE WEEK APART PRIOR TO WORK UP	NA	YES	YES	YES	YES
COVID-19 TEST REPORT. AT IDMS & PRE SCREEN TESTS FOR STEM CELL DONATION FITNESS.	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
COVID-19 TEST ON DAY 4 OF MOBILISATION	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	POSITIVE
STEM CELL GRAFT	COLLECT PBSC	COLLECT AFTER THE DEFERRAL PERIOD: PBSC	COLLECT AFTER THE DEFERRAL PERIOD: PBSC	LOOK FOR ALTERNATIVE DONOR OR RE EVALUATE AFTER 3 MONTHS	LOOK FOR ALTERNATIVE DONOR OR RE EVALUATE AFTER 3 MONTHS
OTHER	DONOR TO BE CONTACTED 14 DAYS AFTER HARVEST FOR ANY SYMPTOMS RELATED TO COVID-19	DONOR TO BE CONTACTED 14 DAYS AFTER HARVEST FOR ANY SYMPTOMS RELATED TO COVID-19	DONOR TO BE CONTACTED 14 DAYS AFTER HARVEST FOR ANY SYMPTOMS RELATED TO COVID-19	DONOR TO BE CONTACTED 14 DAYS AFTER HARVEST FOR ANY SYMPTOMS RELATED TO COVID-19	DONOR TO BE CONTACTED 14 DAYS AFTER HARVEST FOR ANY SYMPTOMS RELATED TO COVID-19

# Media Coverage Helps Increase Awareness

## Radio and TV Coverage



**SHARE THE JOY OF GIFTING A LIFE !  
YOU TOO CAN #GiftALife !  
[www.datri.org/join](http://www.datri.org/join)**






**RESULTS**




## Collections After Lockdown – April 2020 onwards



**98** In 2020

WMDA Virtual Meetings Week 2021

# Donors Registered



**0.46 Million** Donors registered till Mar 2021

WMDA Virtual Meetings Week 2021



IMPOSSIBLE


POSSIBLE

Thank  
you

# Ezer Mizion Challenges and Solutions during the Covid-19 Pandemic

Sigal Manor






# Covid-19 Pandemic Timelines in Israel

2019

2020

2021





# Our Challenges

- **Donors' availability**
  - Increase in donor deferral (Covid-19 diagnosis / quarantine due to exposure)
  - Increase in donor reluctant to donate
  - Difficulties to travel to collection site
- **Staff availability and internal operations**
  - Working from home/bubbles at office
  - IT challenges: provided access to work from home for all the staff
  - Difficulties due to closure of schools and kindergartens
- **Product Quality**
  - Cryopreservation
  - Emergency cryopreservation at Collection Center
- **Transportation**
  - Closing of national borders
  - Flights' cancellations
  - Entrance ban of non-Israeli couriers
  - Transport of frozen products (dry shippers)

# Transportation Challenges




- Significant time periods with almost no commercial flights available (*March-April 2020; Jan-March 2021*)
- Many last-minute flights cancellations
- All citizens, either Israeli and non-Israeli, must quarantine for 14 days when entering the country
  - Only recently vaccinated Israeli citizens received waiver from quarantine if they provide PCR SARS-Cov-2 Neg result when arriving at the Israeli airport
- Non-Israeli citizens cannot enter Israel
  - Waiver was not provided to non-Israeli couriers
- On Jan 26<sup>th</sup> 2021 the Israeli authorities aggravated the restrictions for Israeli citizens to travel abroad thus causing vast difficulties to deliver products from Israel to international TCs
  - These restriction were removed only on March 21<sup>th</sup> 2021

# Our Solution



- Use the services of the Israeli branch of Royale International
- Royale is represented in 22 countries globally, has 42 strategic offices and 27+ years of experience
- Royale's Life Science Division:
  - Provide high-end logistics solutions for healthcare and pharmaceutical industries
  - 20+ years of experience handling time-sensitive temperature-controlled products worldwide (Organs, Stem cells, Clinical trials, API's, Medical devices, Drug development and Commercial medicines)
  - Compliant with the GDP requirements and ISO 9001




# Mishel Zrian – One of a kind story

- ✈ 328 consecutive days in a row under mission !
- ✈ 50 cities around the globe
- ✈ 31 different cities in the US
- ✈ 263 flights
- ✈ 110 USA domestic flights
- ✈ 83 SC products deliveries




# Shipments per country

- We found a way to transport every product anywhere it was needed in the world




# Transit Time & Shipment Type

TRANSIT TIME




**\*\* 75% Delivered within 24 hours**

SHIPMENT TYPE





# The Vaccination Operation in Israel




55% of the Israeli population received the first vaccine dose

85% of the Israeli population >16 yo are either vaccinated or recovered from Covid



\*22.3.21

 **THANK  
YOU!  
DONOR**



The image shows a grid of 16 video call windows from a virtual meeting. Each window features a participant holding a white sign with the Hebrew text "תודה תורם" (Thank you donor), a red heart icon, and a hashtag symbol. The participants are: Tal Miller, Sigal Manor, Talia, חלי רבינשטיין, מוריה, Karin zamir, etti weisz, Yehudit Eitel, Ravid Swisa, ניצן פריימן, לאה פניגשטיין, Keren hag, Dvory, Adi, Naomi's iPhone, and Michal Gordin. At the bottom of the grid is a video call control bar with icons for Top Video, Security, Participants (16), Chat, Share Screen, Record, and Reactions.

WMDA Virtual Meetings Week 2021



*Thank You!*

# 2021-03 WMDA Virtual Meetings

## Introduction


These are unusual times for everyone but this is also a time when innovation and connecting is more important than ever! The WMDA Virtual Meetings Week has been a celebration of innovation and will feature success stories of WMDA project groups. New areas are coming up: virtual donor drives, cryopreserved products, effective registry operations during and after the pandemic. Watch the recordings of our virtual meetings week.



WMDA Virtual Meetings - Click on title to watch the recording

View the recordings by clicking on the titles.

	Pillar 1: Optimising Search, Match & Connect	Pillar 2: Supporting Global Development	Pillar 3: Promoting Donor Care	Pillar 4: Ensuring Quality	Foundation
	<b>March 22</b>	<b>March 23</b>	<b>March 24</b>	<b>March 25</b>	<b>March 26</b>
	<p><a href="#">New Comers Coffee - slides</a></p> <p>Are you new as WMDA member? We highly recommend to watch this recording. On the slides you will see how you can become involved in WMDA.</p> <ul style="list-style-type: none"> <li>• <a href="#">How to connect with WMDA working groups?</a></li> <li>• <a href="#">Online education - what can WMDA offer?</a></li> </ul>	<p><b>Connect with WMDA:</b> A casual meeting with WMDA office staff members to ask questions/</p> <p><i>No recording available.</i></p>	<p><b>Connect with WMDA:</b></p> <p>Mirjam Fechter, medical consultant of WMDA, explains how to report a SEAR/SPEAR to WMDA.</p> <p><i>Panelists: Mirjam Fechter, Alicia Venter</i></p>	<p><b>Connect with WMDA:</b> A casual meeting with WMDA office and members of the Accreditation Committee to respond to questions in relation to Accreditation.</p> <p><i>No recording available.</i></p> <p><i>Panel: Nicoletta Sacchi, Felix Bussmann, Matilde Lartategui</i></p>	<p><a href="#">Inspire &amp; Connect - Consultation Group new Registries and DCs - slides</a></p> <p>A new group that has been established within WMDA. This group will serve as a consultation group for new and emerging registries.</p>
	<p><a href="#">The WMDA perspective on data security and privacy - slides</a></p> <p>The Security and Privacy Committee has worked on a simple service for all WMDA members to do a risk assessment. Your registry will learn what steps to take for evaluation of compliance with law and regulations in the area of data privacy. You can also get free advice from our security experts.</p>	<ul style="list-style-type: none"> <li>▪ <a href="#">Champions Ceremony - World Marrow Donor Day 2020</a></li> <li>▪ <a href="#">WMDD Prize Winners 2020</a></li> </ul> <p>The sixth edition of World Marrow Donor Day was a virtual success. Watch the recording and inspire how the winners organised their day</p> <p>The winners:</p> <ul style="list-style-type: none"> <li>• Grand Prize- National Registry of Romania</li> <li>• Originality Prize - REDOME Brazil</li> <li>• Incentive Prize - DATRI India</li> </ul>	<p><a href="#">WMDA insights - SEAR /SPEAR Annual report 2020 -</a></p> <p>The S(P)EAR Committee presented the WMDA S (P)EAR Annual Report 2020.</p> <p><a href="#">slides Thilo Mengling &amp; slides Mirjam Fechter combined deck</a></p>	<p><a href="#">Table Talk - Brainstorming Session - slides</a></p> <p>A new chair and chair-elect of the Quality &amp; Regulation WG started on January 1, 2020. During this session they introduce themselves and brainstorm about future projects.</p> <ul style="list-style-type: none"> <li>• <a href="#">Slides</a></li> </ul>	<p><a href="#">Meeting Pearls - slides</a></p> <p>Serving you the pearls of the WMDA virtual meeting week: the most revealing insights, mind blowing highlights, inspiring connections, challenging quotes, and opportunities.</p>

<p><b>Optimising Search, Match &amp; Connect/EMDIS - slides</b></p> <p>What is and who are needed to accelerate 'making connection with all registries with a single click'. Will initiatives such as EMDIS, Connect, Search &amp; Match Service help in this ambition? What new concepts should we think of? What change in registry communication is needed to connect globally.</p>	<p><b>Supporting Global Development - Registries - slides</b></p> <ul style="list-style-type: none"> <li>Welcome - Dunia Jawdat</li> <li>Global Trends Report preliminary results - Monique Jöris</li> <li>Results of WMDA Survey - Ann O'Leary</li> <li>What did your registry change in operations? <ul style="list-style-type: none"> <li>Brazil - REDOME perspective</li> <li>India - DATRI perspective</li> <li>Israel - Ezer Mizion perspective</li> </ul> </li> <li>Update projects Donor Registries WG <ul style="list-style-type: none"> <li>Search Coordinator Paper Review - Valerie Stewart</li> <li>Insurance - Jane Ward /Ann O'Leary</li> <li>Patient Follow Up - Deborah Buk</li> </ul> </li> <li>Closure</li> </ul>	<p><b>Promoting Donor Care - slides</b></p> <ul style="list-style-type: none"> <li>Welcome - Thilo Mengling</li> <li>The impact of COVID-19 and vaccination on donor eligibility - Hung Yang</li> <li><b>Ethical Issues:</b> <ul style="list-style-type: none"> <li>Genetic findings and donor implications : Angharad Pryce (Anthony Nolan)</li> <li>Related donors - challenges and special considerations: Jason Oakes (NMDP)</li> </ul> </li> <li><b>Mobilization:</b> <ul style="list-style-type: none"> <li>Plerixafor data &amp; Magenta study: Meghann Cody (NMDP)</li> <li>Donor self-administration of GCSF: Paul Johnson (Anthony Nolan)</li> </ul> </li> <li><b>Cryopreservation:</b> <ul style="list-style-type: none"> <li>Cryopreservation issues, concerns, and considerations: Chloe Anthias (Anthony Nolan)</li> </ul> </li> <li>Closure</li> </ul>	<p><b>Ensuring Quality - slides</b></p> <p>How to address quality management during a pandemic? There will be discussion on remote audits, Key Performance Indicators on Health Availability Check, cryopreservation, listing of cryopreserved products.</p> <ul style="list-style-type: none"> <li>Welcome - Nicoletta Sacchi</li> <li>WMDA Standards Committee - Dena Mercer:</li> <li>Challenges with compliance to WMDA Standards during the pandemic, and discussion of potential solutions.</li> <li>Status of Accreditation in the Time of the Pandemic: Remote Audits and Other Challenges - Carolyn Hurler</li> <li>WMDA Quality &amp; Regulation WG - Susie Joron</li> <li>Closure</li> </ul>	<p><b>WMDA General Membership Meeting - slides</b></p> <ul style="list-style-type: none"> <li>Welcome - Bronwen Shaw</li> <li>Update on WMDA finances - Oliver Kuersteiner</li> <li>Update from the pillars\</li> <li>Award ceremony qualified /accredited registries</li> <li>Update nomination committee</li> <li>Next WMDA meeting</li> <li>Closure</li> </ul>
<p><b>Junior lab</b></p> <p>This session aims to bring together early career registry staff, new WMDA members and young professionals in the field of HSC transplantation to connect with senior WMDA members.</p> <p>Are you a young professional, working in the field of Hematopoietic Stem Cell Transplantation, with an interest to collaborate internationally? Be sure to join this session with Dr. Bronwen Shaw, MD, PhD, Scientific Director Center for International Blood &amp; Marrow Transplant Research (CIBMTR) and President of the WMDA and also with Dr. Dunia Jawdat, PhD, D(ABMLI), MD, Director at the Saudi Stem Cell Donor Registry and the Cord Blood Bank KAIMRC and Board Member of WMDA.</p>	<p><b>Supporting Global Development - Cord Blood Banks - slides</b></p> <p>Be inspired by the latest cord blood insights from Europe, America and Oceania. Useful to define your cord blood banking focus and strategy.</p> <ul style="list-style-type: none"> <li>Welcome - Heidi Elmoazzen <ul style="list-style-type: none"> <li>WMDA Cord Blood WG - Heidi Elmoazzen</li> <li>What is important in the selection of a cord blood unit? <ul style="list-style-type: none"> <li>US perspective - Donna Regan</li> <li>UK perspective - Irina Evseeva</li> <li>Australian perspective - Ngairé Elwood</li> </ul> </li> <li>Global Trend Report preliminary results - Monique Jöris</li> <li>Questions /Open discussion</li> <li>Closure</li> </ul> </li> </ul>		<p><b>Table talk - Couriers - slides</b></p> <p>The pandemic has resulted in increased interest for international exchange of cells, but transportation of cells has been complicated due to varying traveling regulations per country. In this session we will hear stories about transportations during the pandemic. We will also talk about the importance of quality for couriers and we will look into what WMDA can do for this aspect.</p> <p><u>This webinar is supported by</u></p> 	

<p><b>Table talk - Lost in translation? Data Dictionary Guide - slides Ying Li &amp; slides Zhihong He</b></p> <p>Maintaining an effective and high quality donor database is critical in identifying the most suitable donor(s) when needed. This session will take you on a deep dive into the WMDA's efforts to sustain such a database.</p> <p>Two presentations will be delivered:</p> <ul style="list-style-type: none"> <li>• Ying Li of the Data Dictionary Committee will report on their main responsibilities, RFC processes and current projects</li> <li>• Zhihong He will present findings on the current quality of Search &amp; Match and what <u>you</u> can do to assist in improving it.</li> </ul>	<p><b>Inspire &amp; Connect - World Marrow Donor Day 2021 - slides</b></p> <p>Be inspired by the members of the WMDD Task Force and give your feedback on their awesome programme for this year's edition of World Marrow Donor Day. Useful to start your registry's focus on World Marrow Donor Day 2021!</p> <p>T</p>	<p><b>Table talk - Ethical insights - slides</b></p> <p>What's happening in Donor Care and what can we expect for the future? What does the medical working group need to take into account and should we get involved in new areas of treatment to which our donors can contribute?</p> <ul style="list-style-type: none"> <li>• <b>Ethical Issues:</b> <ul style="list-style-type: none"> <li>• Genetic findings and donor implications : Angharad Pryce (Anthony Nolan)</li> <li>• Related donors - challenges and special considerations: Jason Oakes (NMDP)</li> </ul> </li> <li>• <b>Mobilization:</b> <ul style="list-style-type: none"> <li>• Plerixafor data &amp; Magenta study: Meghann Cody (NMDP)</li> <li>• Donor self-administration of GCSF: Paul Johnson (Anthony Nolan)</li> </ul> </li> <li>• <b>Cryopreservation:</b> <ul style="list-style-type: none"> <li>• Cryopreservation issues, concerns, and considerations: Chloe Anthias (Anthony Nolan)</li> </ul> </li> </ul>	<p><b>Inspire &amp; Connect - Cellular Therapy - slides</b></p> <p>The first meeting of the WMDA Cellular Therapy Task Force to introduce themselves and to get input from the membership on areas to work on.</p>
<p><b>Table talk - Matching Insights - slides</b></p> <p>Be inspired by the alternative matching algorithms of WMDA: Atlas and Hap-E Search.</p>	<p><b>Connect with WMDA:</b> A casual meeting with WMDA office staff members to ask questions/ <i>No recording available.</i></p>	<p><b>Connect with WMDA:</b> A casual meeting with WMDA office staff members to ask questions/ <i>No recording available.</i></p>	<p><b>Connect with WMDA:</b> A casual meeting with WMDA office staff members to ask questions/ <i>No recording available.</i></p>


# Report for WMDA Virtual Meetings Week 2021 - Evaluation

## Response Counts



Totals: 36

### 1. How do you rate our webinar week?



2. Do you have any feedback for us, any improvements we can work on? We would be happy to know your thoughts.

## ResponseID Response

---

- |    |   |
|----|---|
| 1  | It was a really well-filled program, with a good division between the pillars, which in the meantime are also really "in the minds" of members. Sometimes I think the IT part came over a bit too big and too technical. What I missed were "stories" from smaller registries: the big parties sometimes came over dominant. Smaller registries could feel intimidated. The presentation was friendly, open and professional. The possibilities of feedback came across as sufficient. What was lacking was intercultural exchange or regional focus (read: specific regional problems) : with English as the central language, this is hard to avoid. All in all: congratulations! |
| 3  | I am happy that the vote was positive for hybrid meetings in the future. Is it possible to get a Certificate or letter of attendance. Thank you again for everything. You are a great team of good people. Great Job (:   |
| 4  | It is very useful for us to have the recorded presentations and slides. Congratulations.  |
| 5  | All the sessions were superb. I think everything is perfect.  |
| 7  | Webinars fill a huge gap during the pandemic period The WMDA meeting was extremely informative and motivating for me and my friends   |
| 8  | Congratulations to WMDA team for this great Meeting.  |
| 12 | Good work! Keep it up!  |
| 13 | It would be nice if time management of certain sessions was better so there would still be time for Q&A. Less content or longer sessions, both would be fine. However, discussion is an essential part of any meeting and it is a shame there sometimes was no time for that.   |

## ResponseID Response

---

14	At a meeting, it would be nice to be able to see a list of participants in all webinars as a normal participant.
16	Congratulations and thank you.
18	I think this was very close to the best that could be done in terms of a virtual meeting. Obviously, key benefits of an in-person conference, such as the possibility to discuss/chat after a session, cannot be replaced; therefore I'm looking forward to a -hopefully- not so distant in-person event.
20	slower exposition by the speaker for a clear understanding of all auditors
23	Great opportunity to keep updated on the last information in the area.
28	well done
29	For virtual meetings, all the speakers should use the background with the topic of the day. Congratulation for great organizing of virtual meetings week 2021..
32	For people who do not travel to in-person conferences, the pandemic has given us an incredible opportunity to be much more involved and get a taste of what is happening in the WMDA and BMT community. When Martine joined the WMDA I'm sure no-one asked her "Are you good at moderating webinars and video sessions?" but she consistently does an excellent job. She makes it look easy but I'm sure it's not. I don't recall any technical hitches and that is also to be commended when participants are in many different countries. Thanks for an excellent and informative week. David Gift of Life
35	- do questions right after each presentation and not only at the end.
37	All good thanks

# WMDA Virtual Meeting November 2021

WMDA Virtual Meetings | Cellular therapy | 8-10 & 15-17 Nov. 2021

## Schedule and meeting info

### 8 November 2021 | Pillar 3, Promoting Donor Care

(Click the title to view the recording)

<b>13h00-13h30CET: Introduction Session</b>		
<p><b>Cellular Therapy - Donor Care</b></p> <p><i>Moderators:</i></p> <p>Steven Devine - Chief Medical Officer, Be The Match BioTherapies, Chief Medical Officer, NMDP/Be The Match Associate Scientific Director, CIBMTR</p> <p>Thilo Mengling - Director International Medical Science DKMS - <i>WMDA Board Member Pillar Donor Care</i></p>	<p><b>Welcome</b></p> <p><b>Introduction of panelists</b></p> <p><b>Workshop</b> on ethics of donating stem cells for other purposes than transplantation (e.g. research), how to ensure donor safety.</p> <p>View from different expertise areas -</p> <ul style="list-style-type: none"> <li>• Current situation in cellular therapy from a global perspective</li> <li>• The biggest hurdles to cellular therapy in different fields of expertise and regions</li> </ul>	<p><b>Panelists</b></p> <ul style="list-style-type: none"> <li>• Eline Schiks - Ethicist</li> <li>• Joy Aho - Senior Product Manager at Be The Match BioTherapies</li> <li>• Sharanya Ramakrishnan - Postdoctoral Fellow in Cellular Therapy (CAR-T manufacturing) and Apheresis at Tata Medical Center Kolkata</li> <li>• Salmah Ahmed - Director of Quality and Regulation at Anthony Nolan</li> <li>• Francisco Barriga - Board of Directors at DKMS Chile</li> <li>• Greg Whitehead - Chief Quality Officer at Rubius Therapeutics</li> </ul>
<b>13h30-15h00CET: Focus Session</b>		
<p><b>Focus Session - Translating your discovery - what is the future role of a donor?</b></p> <p><i>Moderators:</i></p> <p>Steven Devine - Chief Medical Officer, Be The Match BioTherapies, Chief Medical Officer, NMDP/Be The Match Associate Scientific Director, CIBMTR</p> <p>Thilo Mengling - Director International Medical Science DKMS - <i>WMDA Board Member Pillar Donor Care</i></p>	<p><b>Areas that will be discussed</b></p> <ul style="list-style-type: none"> <li>• Genetic information: protection and communicating genetic findings</li> <li>• What happens with unused cells?</li> <li>• How do you explain to donors that their donation will be used for cellular therapy instead of for a specific patient in need of a transplant?</li> <li>• Should there be separate registries or registration processes for donors who only wish to donate directly to patients and donors who are willing to also donate for other purposes like cellular therapy?</li> <li>• Should donors be reimbursed in some way for donations made to create cellular therapies?</li> <li>• Should the pharmaceutical industry or the donor registry be responsible for post-donation donor care expenses?</li> </ul>	<p><b>Panelists</b></p> <ul style="list-style-type: none"> <li>• Eline Schiks - Ethicist</li> <li>• Joy Aho - Senior Product Manager at Be The Match BioTherapies</li> <li>• Sharanya Ramakrishnan - Postdoctoral Fellow in Cellular Therapy (CAR-T manufacturing) and Apheresis at Tata Medical Center Kolkata</li> <li>• Salmah Ahmed - Director of Quality and Regulation at Anthony Nolan</li> <li>• Francisco Barriga - DKMS Chile</li> <li>• Greg Whitehead - Chief Quality Officer at Rubius Therapeutics</li> </ul>



## 9 November 2021 | Pillar 1, Optimising 'Search Match & Connect'

(Click the title to view the recording)

<b>13h00-14h00CET: Plenary Session</b>		
<b>Cellular Therapy - Search, Match &amp; Connect</b>  <i>Moderators:</i>  Alicia Venter - pillar coordinator Search, Match & Connect  Julie Smolich - Senior Vice President, Provider Services at Be The Match	<b>Welcome</b>  <b>Educational presentations</b>  <ol style="list-style-type: none"> <li>1. <a href="#">Opportunities for registries within the Cell and Gene Therapy supply chain</a></li> <li>2. <a href="#">Allogeneic starting materials</a></li> <li>3. <a href="#">Donor Characterization: Selecting donors for success</a></li> </ol>	<b>15-minutes presentations from:</b>  <ol style="list-style-type: none"> <li>1. Daniel Gibson - Director of Cell and Gene Therapy Services at Anthony Nolan</li> <li>2. Tim Tripp - Director Cell and Gene Therapies Operations at Be The Match BioTherapies</li> <li>3. Martin Maiers - Vice President Innovation at Be The Match</li> </ol>
<b>14h00-15h00CET: Conversation Forum</b>		
<i>Moderators:</i>  Alicia Venter - pillar coordinator Search, Match & Connect  Julie Smolich - Senior Vice President, Provider Services at Be The Match	<b>Conversation questions</b>  <ul style="list-style-type: none"> <li>• How do we ensure consistency of processes and products to meet the Cell &amp; Gene Therapy (CGT) needs (from consent alignment to product delivery)?</li> <li>• What is the role of registries as donor advocates to the CGT industry?</li> <li>• What role do we play in ensuring donor recruitment, enrollment and collection remains 'humanised' through the supply chain and Advanced Therapy Medicinal Products (ATMP) development?</li> </ul>	<b>Facilitators</b>  <ul style="list-style-type: none"> <li>• Daniel Gibson - Director of Cell and Gene Therapy Services at Anthony Nolan</li> <li>• Tim Tripp - Director Cell and Gene Therapies Operations at Be The Match BioTherapies</li> <li>• Martin Maiers - Vice President Innovation at Be The Match</li> <li>• Julie Smolich - Senior Vice President, Provider Services at Be The Match</li> <li>• Alicia Venter - WMDA</li> <li>• Mark Melchers - WMDA</li> </ul>

## 10 November 2021 | Junior Lab

(Click the title to view the slides)

<b>13h00-14h00CET: Plenary Session</b>	
	This session is designed for people who are interested in using a mentor network, as new-comers/high potentials with an ambition to be involved within WMDA. During the session we will check with the group what they would be looking for so that after the session mentors can be recruited. It will start with introduction of the project and project group members, including scope of the project. This will be followed by an introduction of the four pillars and end with the mentoring program goals requesting input. Prepared and facilitated by: Josefine Teeler, Shannon Stampe, Juliana Villa, Yehudit Eitiel, Nadia Bagheri and Martine Schuit

## 15 November 2021 | Pillar 4, Ensuring Quality

(Click the title to view the recording)

<b>13h00-14h00CET: Business of Discovery</b>		
<b>Cellular Therapy - Ensuring Quality</b>  <i>Moderators:</i>  JonathanPearce - Chief Executive Officer at DKMS UK  Joannis Mytilineos - Chief Medical Officer at ZKRD Germany	<b>Welcome</b>  <b>Focused presentations</b>  <ol style="list-style-type: none"> <li>1. <a href="#">Donor consent policy/standard</a></li> <li>2. <a href="#">Scope of additional standard/change of current WMDA Standards (for all registries, or only for the registries that will include cellular therapy)</a></li> <li>3. <a href="#">Other players in the field (transplant centres, apheresis centres, etc)</a></li> <li>4. <a href="#">Transport &amp; courier requirements</a></li> </ol>	<b>10-minutes presentations from</b>  <ol style="list-style-type: none"> <li>1. Anna Rehlich – Cell Therapy Operations Manager at Gift of Life</li> <li>2. Dena Mercer - Head of Stem Cells Program Strategy &amp; Business Development at Canadian Blood Services <i>chair of the WMDA Standards Committee</i></li> <li>3. Khaled El-Ghariani- consultant at NHS Blood and Transplant</li> <li>4. Ray Hornung - Director, Logistics &amp; Emergency Preparedness at NMDP</li> </ol>
<b>14h00-15h00CET: mini workshops</b>		
<i>Moderators:</i>  JonathanPearce - Chief Executive Officer at DKMS UK  Joannis Mytilineos - Chief Medical Officer at ZKRD Germany	<b>What do you think from a Quality &amp; Regulatory Point of View?</b>  <ul style="list-style-type: none"> <li>• How do we ensure donor involvement and understanding in the donation (and possible modification in some cases) of cells for new therapies, so that they are supportive of the changes and developments?</li> <li>• Donation processes – what changes might there be for donor preparation and assessment and for registries/collection centres dealing with new procedures and therapies?</li> <li>• Transport, logistics and Customs issues - any specific requirements /standards/regulations that need to be considered?</li> <li>• What is the experience in different countries? What changes might new cellular therapies bring?</li> </ul>	<b>Business of Discovery Discussions - Panelists</b>  <ul style="list-style-type: none"> <li>• JonathanPearce - Chief Executive Officer at DKMS UK</li> <li>• Joannis Mytilineos - Chief Medical Officer at ZKRD Germany</li> <li>• Salmah Ahmed - Director of Quality and Regulation at Anthony Nolan</li> <li>• Annette Rasche - Head Of Search and Transplant Services at ZKRD</li> <li>• Ray Hornung - Director, Logistics &amp; Emergency Preparedness at NMDP</li> <li>• Anna Rehlich – Cell Therapy Operations Manager at Gift of Life</li> </ul>

## 16 November 2021 | Pillar 2, Supporting Global Development

(Click the title to view the recording)

<b>13h00-14h00CET: Business of Discovery</b>		
<b>Cellular Therapy - Global Development</b>  <i>Moderators:</i>  Wouter Van't Hof- Director, Processing Facility and CEO of our Cell Therapy Incubator Cleveland Cord Blood Center  Nicholas Dibdin - Associate Director, Stem Cells Operations at Canadian Blood Services	<b>Welcome</b>  <b>Educational presentations</b>  <ol style="list-style-type: none"> <li>1. <a href="#">Perspective non-traditional application of cord blood and its derived products in cell therapy</a></li> <li>2. <a href="#">Novel cell and gene therapies: an outlook to the future of cellular therapy</a></li> <li>3. <a href="#">Another way to cure by engineered cells</a></li> </ol>	<b>20-minutes presentations from</b>  <ol style="list-style-type: none"> <li>1. Arun Prasath - Director Singapore Cord Blood Bank</li> <li>2. Joy Aho - Senior Product Manager at Be The Match BioTherapies</li> <li>3. Prof. Dr. Gerhard Ehninger - MD, CMO AvenCell, Boston/Dresden, CEO Cellex Cell Professionals, Cologne</li> </ol>

<b>14h00-15h00CET: Focus Session</b>		
<p><i>Moderators:</i></p> <p>Wouter Van't Hof- Director, Processing Facility and CEO of our Cell Therapy Incubator Cleveland Cord Blood Center</p> <p>Nicholas Dibdin - Associate Director, Stem Cells Operations at Canadian Blood Services</p>	<p><b>Business of Discovery Workshop - plenary discussion</b></p> <ol style="list-style-type: none"> <li>1. Repurposing Cord Blood (Wouter Van 't Hof)</li> <li>2. Registry impacts/concerns/considerations (Nicholas Dibdin)</li> <li>3. (Re)Consent for donors to enable donation for Cellular Therapy purposes; ethical perspective (Eline Schiks, ethicist)</li> <li>4. Novel cell and gene therapies: an outlook to the future of cellular therapy (Joy Aho)</li> <li>5. Perspective non-traditional application of cord blood and its derived products in cell therapy (Arun Prasath)</li> <li>6. Another way to cure by engineered cells (Gerhard Ehninger)</li> </ol>	<p><b>Business of Discovery Discussions - Panelists</b></p> <ol style="list-style-type: none"> <li>1. Wouter Van't Hof- Director, Processing Facility, CEO of Cell Therapy Incubator Cleveland Cord Blood Center</li> <li>2. Nicholas Dibdin - Associate Director, Stem Cells Operations at Canadian Blood Services</li> <li>3. Eline Schiks - Ethicist</li> <li>4. Joy Aho - Senior Product Manager at Be The Match BioTherapies</li> <li>5. Arun Prasath- Director Singapore Cord Blood Bank</li> <li>6. Prof. Dr. Gerhard Ehninger - MD, CMO AvenCell, Boston/Dresden, CEO Cellex Cell Professionals, Cologne</li> </ol>

## 17 November 2021 | General Membership Meeting

(Click the title to view the recording)  
(Find the slide deck via this link)

<b>12h00-14h30CET: Plenary Session</b>	<ol style="list-style-type: none"> <li>1. Welcome by Bronwen Shaw <ol style="list-style-type: none"> <li>a. Welcome to National Bone Marrow Donors Registry named after Vasya Perevoshchikov as new provisional member</li> </ol> </li> <li>2. Approval of the minutes (see: <a href="#">Minutes General Membership Meeting</a>)</li> <li>3. Update from WMDA Administrative Committees <ol style="list-style-type: none"> <li>a. Finance, Audit, Governance, Fundraising - Oliver Kürsteiner</li> <li>b. Nomination - Jeff Szer</li> </ol> </li> <li>4. Update from WMDA Pillar Leadership <ol style="list-style-type: none"> <li>a. Pillar 1: Search, Match &amp; Connect and EMDIS - Henny Braund/Mike McCullough <ol style="list-style-type: none"> <li>i. Donor Readiness Score - Ying Li</li> <li>ii. ADCU - Jeff Wren</li> <li>iii. EMDIS Goes WMDA - Julia Pingel</li> </ol> </li> <li>b. Pillar 2: Global Development - Dunia Jawdat <ol style="list-style-type: none"> <li>i. Search Coordinator Education</li> <li>ii. Junior Lab</li> <li>iii. Communication</li> <li>iv. Cord Blood: webinars, NIMA, ready-to-ship, Cord Blood Connect</li> <li>v. Global Trends Report: new questions</li> <li>vi. New Organisations including update WMDA handbook</li> <li>vii. Patient Follow Up</li> <li>viii. RUN project</li> <li>ix. Highlights WMDD</li> </ol> </li> <li>c. Pillar 3: Donor Care - Thilo Mengling <ol style="list-style-type: none"> <li>i. S(P)EAR</li> <li>ii. Donor Suitability</li> <li>iii. Donor Genetic findings working group</li> </ol> </li> <li>d. Pillar 4: Quality &amp; Award Ceremony Accredited Registries - Lydia Foeken <ol style="list-style-type: none"> <li>i. ISO certification - Carolyn Hurley</li> <li>ii. WMDA Standards Committee - Dena Mercer</li> <li>iii. Certificate ceremony - Bronwen Shaw</li> </ol> </li> </ol> </li> <li>5. DKMS Collaboration Grant - Lydia Foeken</li> <li>6. Introduction Matthew Seftel, President Elect</li> <li>7. Thank you</li> <li>8. Closure</li> </ol>
--	--


# Report for WMDA Virtual Meetings on Cellular Therapy November 2021 - Evaluation

## Response Counts



Totals: 7

## 1. How do you rate the WMDA Virtual Meetings on Cellular Therapy?



2. Do you have any feedback for us, any improvements we can work on? We would be happy to know your thoughts.

ResponseID	Response
------------	----------

1	The topic is still quite new and the role of registries vague - however, it is good to keep this topic on the agenda as things continue to develop in this field.
---	---

2	Would it be possible to incorporate more collaborative tools during the sessions (i.e. live, interactive polling etc).
---	--

4	Congratulations and thanks a lot, I have got information our registry and Cord Blood Bank really need. My colleagues are happy to be able to watch recordings.
---	--

6	The content of the sessions was rather repetitive - it could have been presented much more compressed, more than one time the same person were speaking in different sessions and also in the "warm-up" meetings.... not so much learnings and exchange as usual - there would have been other relevant topics to discuss.
---	--

## Appendix 8

Screenshots of all recordings for the Virtual Meetings and educational webinars in 2021 with the amount of views on 7 December 2021 since the video was uploaded to YouTube. The screenshots have been added in chronological order.

**DKMS**  
WE DELETE BLOOD CANCER

**VIRTUAL DRIVES AND OTHER WAYS TO MANAGE DONOR RECRUITMENT DURING COVID 19**

Sabine Hildebrand

COVID-19  
Get the latest information from the WHO about coronavirus. [LEARN MORE](#)

See more resources on Google


WMDA Educational Webinar: Virtual Drives and other ways to manage Donor Recruitment during Covid19  
Unlisted  
52 views • 22 Jan 2021

**WMDA**  
matching donors • serving patients

**Cord Blood Unit Selection:  
Shortlisting and detailed unit report analysis**

WMDA Search Coordinator Webinar Series  
2021-01-28  
Irina Evseeva, Laila Roberts, and Roger Horton

WMDA Educational Webinar for Search Coordinators: Cord Blood Unit Selection  
Unlisted  
89 views • 28 Jan 2021



The video player shows a slide with the WMDA logo (a globe icon and the text 'WMDA matching donors • serving patients') at the top. The main title is 'Recommendations for the selection of unrelated donors and cord blood units for allogeneic stem cell transplant'. Below the title, it says 'WMDA Search Coordinator Webinar Series' and '2021-02-25'. The speakers are listed as 'Ioannis Politikos, Bronwen Shaw, and Stephen Spellman'. A small video inset in the top right corner shows a woman speaking. The video progress bar at the bottom indicates 0:48 / 59:54.

WMDA Monthly Webinar for Search Coordinators Feb '21: Recommendations for Selection of MUDs and CBUs

Unlisted

50 views • 26 Feb 2021

0 DISLIKE SHARE SAVE ...



The video player shows a slide with a blue background and white text. The title is 'Jumping Generations - Recruiting Gen Z'. Below the title, it says 'By Ryan Peña' and 'Be the Match-NMDP'. The WMDA logo is in the bottom right corner. A small video inset in the top right corner shows a man speaking. The video progress bar at the bottom indicates 0:53 / 56:40.

WMDA Webinar Series WMDA Communications Group: Jumping Generations - Recruiting Gen Z by Ryan Pena

Unlisted

14 views • 19 Mar 2021


0 DISLIKE SHARE SAVE ...

## Key milestones achieved since June 2020



### 1. Migrating all WMDA technology to Microsoft's Azure cloud environment

- Done with the support and guidance of the community led Security & Privacy Committee
- Underwent independent penetration testing and peer review
- All efforts made to ensure security of data and GDPR compliance



WMDA Virtual Meetings Week 22 March: Pillar 1, Optimising Search, Match and Connect/EMDIS

Unlisted

65 views • 22 Mar 2021

0 DISLIKE SHARE SAVE ...

## World Marrow Donor Association

Welcome

*Lydia Foeken & Martine Schuit*



WMDA Virtual Meetings Week 22 March: Pillar 1, New Comers Coffee

Unlisted

31 views • 22 Mar 2021

0 DISLIKE SHARE SAVE ...





WMDA Virtual Meetings Week 22 March: Pillar 1, The WMDA perspective on data security and privacy

Unlisted

39 views • 22 Mar 2021

0 DISLIKE SHARE SAVE ...



WMDA Virtual Meetings Week 22 March: Junior Lab Session with Bronwen Shaw and Dunia Jawdat

Unlisted

55 views • 22 Mar 2021

0 DISLIKE SHARE SAVE ...

WMDA Data Dictionary Committee

WMDA Virtual Meeting 22nd March 2021

WMDA Virtual Meeting Week 2021

WMDA

2:40 / 58:43

match done servi stien

A video player interface showing a slide with a blue background and white text. The slide title is 'WMDA Data Dictionary Committee' and the subtitle is 'WMDA Virtual Meeting 22nd March 2021'. The video player includes a progress bar at 2:40 / 58:43, a title 'WMDA Virtual Meeting Week 2021', and a WMDA logo in the bottom right corner. A small video inset in the top right corner shows a woman with glasses speaking.

WMDA Virtual Meetings Week 22 March, Pillar 1: Table talk-Lost in translation? Data Dictionary Guide

Unlisted

27 views • 23 Mar 2021

0 DISLIKE SHARE SAVE ...

Matching Insights

The alternative matching algorithms of the WMDA:  
HAP-E and Atlas

WMDA Virtual Meeting Week 2021

WMDA

0:02 / 41:36

match done servi stien

A video player interface showing a slide with a blue background and white text. The slide title is 'Matching Insights' and the subtitle is 'The alternative matching algorithms of the WMDA: HAP-E and Atlas'. The video player includes a progress bar at 0:02 / 41:36, a title 'WMDA Virtual Meeting Week 2021', and a WMDA logo in the bottom right corner. A small video inset in the top right corner shows two people in a meeting.

WMDA Virtual Meetings Week 22 March, Pillar 1: Table talk-Matching Insights

Unlisted

26 views • 23 Mar 2021

0 DISLIKE SHARE SAVE ...

The video player shows a presentation slide with a blue background and white text. The slide title is "Supporting Global Development" and the subtitle is "CORD BLOOD BANKS". Below the subtitle, it says "Chair: Heidi Elmaozzen, PhD". In the top right corner of the video frame, there is a small inset video of a woman with dark hair. The video player controls at the bottom show a progress bar at 0:02 / 1:13:40, the text "WMDA Virtual Meetings Week 2021", and the WMDA logo with icons for chat, donate, serve, and patients.

WMDA Virtual Meetings Week 23 March, Pillar 2: Supporting Global Development - Cord Blood Banks

Unlisted

53 views • 24 Mar 2021

0 DISLIKE SHARE SAVE ...

The video player shows a presentation slide with a blue background and white text. The slide title is "World Marrow Donor Day 2021" and the subtitle is "Inspire and Connect WMDD Task Force". In the top right corner of the video frame, there is a small inset video of two women. The video player controls at the bottom show a progress bar at 0:00 / 1:02:42, the text "WMDA Virtual Meeting Week 2021", and the WMDA logo with icons for chat, donate, serve, and patients. A "WORLD MARROW DONOR DAY" logo is visible in the bottom left corner of the video frame.

WMDA Virtual Meetings Week 23 March, Pillar 2: Inspire & Connect - World Marrow Donor Day 2021

Unlisted

38 views • 24 Mar 2021

0 DISLIKE SHARE SAVE ...



WMDA Virtual Meetings Week 23 March, Pillar 2: Supporting Global Development - Registries

Unlisted

40 views · 24 Mar 2021

0 DISLIKE SHARE SAVE ...




WMDA Virtual Meetings Week 23 March, Pillar 2: Champions Ceremony - World Marrow Donor Day 2020

Unlisted

53 views · 24 Mar 2021

0 DISLIKE SHARE SAVE ...



The video player shows a presentation slide with a blue background and white text. The slide title is 'Table Talk' and the subtitle is 'Chloe Anthias, Meghann Cody, & Guests'. In the top right corner of the slide, there is a small inset image of a woman with a red heart graphic and the WMDA logo. The video player controls at the bottom show a progress bar at 0:04 / 25:05, the title 'WMDA Virtual Meeting Week 2021', and the WMDA logo with icons for watch, done,ervi, and listen.

WMDA Virtual Meetings Week 24 March, Pillar 3: Table Talk - Ethical Insights

Unlisted

23 views • 25 Mar 2021

0 DISLIKE SHARE SAVE ...



The video player shows a presentation slide with a white background and blue text. The slide title is 'Agenda'. The agenda items are: 'Welcome - Thilo Mengling', 'Spotlight on donor care with the SEAR/SPEAR Annual Report 2020 - Thilo Mengling', 'Optimisation - how to improve reporting? - Mirjam Fechter', and 'Closure'. In the top right corner of the slide, there is a small inset image of a man wearing headphones. The video player controls at the bottom show a progress bar at 0:04 / 48:48, the title 'WMDA Virtual Meetings Week 2021', and the WMDA logo with icons for watch, done,ervi, and listen.

WMDA Virtual Meetings Week 24 March, Pillar 3: WMDA Insights - SEAR/SPEAR Annual report 2020

Unlisted

33 views • 25 Mar 2021

0 DISLIKE SHARE SAVE ...

## Agenda

- Welcome – Thilo Mengling
- The impact of COVID-19 and vaccination on donor eligibility – Hung Yang
- Ethical Issues
  - Genetic findings and donor implications: Angharad Pryce (Anthony Nolan)
  - Related donors – challenges and special considerations: Jason Oakes (NMDP)
- Mobilization
  - Plerixafor data & Magenta study: Meghann Cody (NMDP)
  - Donor self-administration of G-CSF: Paul Johnson (Anthony Nolan)
- Cryopreservation
  - Cryopreservation issues, concerns, and considerations: Chloe Anthias (Anthony Nolan)
- Closure – Thilo Mengling



0:03 / 1:30:03

WMDA Virtual Meetings Week 2021



WMDA Virtual Meetings Week 24 March: Pillar 3, Promoting Donor Care

Unlisted

31 views • 25 Mar 2021

0 DISLIKE SHARE SAVE ...

PILLAR 3 | Promoting Donor Care  
Nobody cares how much you know, until they know how much you care.  
*Theodore Roosevelt*

0:56 / 45:25



WMDA Virtual Meetings Week March 24, Pillar 3: Connect with WMDA

Unlisted

9 views • 25 Mar 2021

0 DISLIKE SHARE SAVE ...

The video player shows a presentation slide with a blue gradient background. The slide text reads: "Inspire and Connect Cellular Therapy", "Cell Therapy Task Force", "Salmah Mahmood Ahmed", and "Julie Smolich". A small video thumbnail in the top right corner shows a woman with glasses and a headset. The player controls at the bottom show a progress bar at 0:00 / 45:04 and the text "WMDA Virtual Meeting Week 2021". The WMDA logo is in the bottom right corner.

WMDA Virtual Meetings Week Task Force Cellular Therapy

Unlisted

15 views • 25 Mar 2021

0 DISLIKE SHARE SAVE ...

The video player shows a presentation slide with a blue gradient background. The slide text reads: "Quality Breakout Session" and "25-03-2021". A small video thumbnail in the top right corner shows a man with glasses and a headset. The player controls at the bottom show a progress bar at 0:02 / 20:32 and the text "WMDA Virtual Meeting Week 2021". The WMDA logo is in the bottom right corner.

WMDA Virtual Meetings Week 25 March, Pillar 4: Table Talk - Brainstorming Session

Unlisted

6 views • 26 Mar 2021

0 DISLIKE SHARE SAVE ...



WMDA Virtual Meetings Week 25 March, Pillar 4: Ensuring Quality

Unlisted

18 views • 26 Mar 2021

0 DISLIKE SHARE SAVE ...



WMDA Virtual Meetings Week 25 March, Pillar 4: Table talk - Couriers

Unlisted

25 views • 26 Mar 2021

0 DISLIKE SHARE SAVE ...



**WMDA's 4 pillars and their coordinators**

1. Optimising Search, Match & Connect – Alicia Venter
2. Supporting Global Development – Martine Schuit
3. Promoting Donor Care – Alicia Venter
4. Ensuring Quality – Matilde Lartategui

WMDA Virtual Meetings Week 2021

WMDA Virtual Meetings Week 2021 Friday 26 March: Meeting Pearls

Unlisted

10 views • 26 Mar 2021

0 DISLIKE SHARE SAVE ...

**Emerging Registry Pathway**

WMDA Taskforce

WMDA Virtual Meeting Week 2021

WMDA Virtual Meetings Week 2021 Friday 26 March: Consultation Group new Registries and Donor Centers

Unlisted

19 views • 26 Mar 2021

0 DISLIKE SHARE SAVE ...




WMDA Virtual Meetings Week Friday 26 March General Membership Meeting

Unlisted

36 views • 26 Mar 2021

0 DISLIKE SHARE SAVE ...



WMDA Webinar: HLA-B leader and survivorship after HLA-MUD transplantation by Effie Peterdorf

Unlisted

140 views • 23 Apr 2021

2 DISLIKE SHARE SAVE ...

# Challenges in the Asia-Pacific Region

William Hwang, MBBS, FRCP  
Medical Director, National Cancer Centre of Singapore  
Professor, Duke-NUS Medical School  
Senior Consultant, Singapore General Hospital

With valuable input from Monique Jöris and Zhihong He

WMDA  
match done enviro client

0:49 / 49:55

WMDA Educational Webinar for Search Coordinators: Challenges in the Asian-Pacific Region by W. Hwang

Unlisted

35 views • 31 May 2021

0 DISLIKE SHARE SAVE ...

# Perspectives in allogeneic search: Case Study

Dr. Valerie Stewart, MSc, PhD  
2021-06-24

WMDA  
match done enviro client

0:43 / 1:02:08

WMDA Educational Webinar | Perspectives in allogeneic search: Case Study by Dr. Valerie Stewart

Unlisted

22 views • 28 Jun 2021

1 DISLIKE SHARE SAVE ...

**Introduction**  
*by Rebecca Pritchard*

Patient Appeals in a Pandemic  
*By Amy Bartlett and Rowena Bentley*

1:35 / 1:01:29

This video player shows a presentation slide with a blue vertical bar on the left. The slide title is 'Introduction by Rebecca Pritchard' and the subtitle is 'Patient Appeals in a Pandemic By Amy Bartlett and Rowena Bentley'. A small thumbnail image in the top right corner shows a woman with the text 'PILLAR 1'. The video player interface includes a progress bar at 1:35 / 1:01:29, a WMDA logo, and standard playback controls.

WMDA Webinar Communication Group: Virtual Patient Appeals by A. Bartlett & R. Bentley, Anthony Nolan

Unlisted

9 views • 2 Jul 2021

0 DISLIKE SHARE SAVE ...

PILLAR 1 | Optimising 'Search & Connect'  
Security, Privacy, Compliance

0:53 / 55:38

This video player shows a man wearing headphones and holding a microphone, speaking. The background features a network diagram and the text 'PILLAR 1 | Optimising Search & Connect Security, Privacy, Compliance'. The video player interface includes a progress bar at 0:53 / 55:38, a WMDA logo, and standard playback controls.

WMDA Security & Privacy Committee on Ransomware

Unlisted

24 views • 13 Sept 2021

0 DISLIKE SHARE SAVE ...



WMDA Cellular Therapy Warm-up Webinar 1.

Unlisted

43 views • 16 Sept 2021

0 DISLIKE SHARE SAVE ...



WMDA Cellular Therapy Warm-up Webinar 2 by Julie Smolich and Steven Devine, NMDP-BeTheMatch

Unlisted

4 views • 28 Oct 2021

0 DISLIKE SHARE SAVE ...

WMDA Virtual Meetings | Cellular Therapy | Pillar 3

Unlisted

108 views • 8 Nov 2021

0 DISLIKE SHARE SAVE ...

WMDA Virtual Meetings | Cellular Therapy | Pillar 1

Unlisted

32 views • 10 Nov 2021

0 DISLIKE SHARE SAVE ...

PILLAR 4 | Ensuring Quality

# Welcome to the WMDA Pillar 4: Ensuring Quality

We will start shortly.  
WMDA thanks our virtual meetings sponsor

ONTIME COURIER  
ONBOARD

WMDA  
matching donors - serving patients

2:04 / 2:00:10 WMDA Virtual Meetings 2021

WMDA Virtual Meetings | Cellular Therapy | Pillar 4

Unlisted

22 views • 17 Nov 2021

0 DISLIKE SHARE SAVE ...

PILLAR 2 | Supporting Global Development

# WMDA Pillar 2: Supporting Global Development for Cellular Therapy

16th November 2021

ONTIME COURIER  
ONBOARD

WMDA  
matching donors - serving patients


0:51 / 1:59:40 WMDA Virtual Meetings | Cellular Therapy | Pillar 2

WMDA Virtual Meetings | Cellular Therapy | Pillar 2

Unlisted

8 views • 17 Nov 2021

0 DISLIKE SHARE SAVE ...




WMDA | General Membership Meeting | 17th November 2021

Unlisted

26 views · 17 Nov 2021

0 DISLIKE SHARE SAVE ...



WMDA Communications Group Meeting 18 November 2021

Unlisted

21 views · 19 Nov 2021

0 DISLIKE SHARE SAVE ...



## References

- 
- <sup>1</sup> WMDA website: [What we do - WMDA](#)
  - <sup>2</sup> Schuit M, Foeken L. D2.2 Resources for registry operations for import/export to EU Member States. 2020 SAVDON, WP1 Grant Agreement number 881553.
  - <sup>3</sup> Stem Cell Matters 59, June 2020. WMDA newsletter: [Stem Cell Matters 59 \(mailchi.mp\)](#)
  - <sup>4</sup> Stem Cell Matters 65, September 2020: [Stem Cell Matters 65 \(mailchi.mp\)](#)
  - <sup>5</sup> WMDA Educational Webinar 'Virtual X-mas Party': <https://youtu.be/7xcvUGQcPDE> (presentation starts at minute 23:45 and ends at minute 29:16)
  - <sup>6</sup> WMDA Global Trends Report 2019 (a copy of specific editions can be requested via [mail@wmda.info](mailto:mail@wmda.info))
  - <sup>7</sup> Foeken L. D2.1 Report on 2020 unrelated hematopoietic stem cell transplantats. 2021 SAVDON, WP1 Grant Agreement number 101015514.
  - <sup>8</sup> WMDA Global Trends Report 2020 (a copy of specific editions can be requested via [mail@wmda.info](mailto:mail@wmda.info))
  - <sup>9</sup> 3887 Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020-Report from World Marrow Donor Association, presented by Stefanie Bernas at ASH 2021 on Monday, December 13, 2021, 6:00 PM-8:00 PM: [Paper: Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 – Report from World Marrow Donor Association \(confex.com\)](#)
  - <sup>10</sup> [Bone Marrow Transplantation \(nature.com\)](#)
  - <sup>11</sup> Jöris M.M. Bernas S.N. et al. WMDA Poster: Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 Report from World Marrow Donor Association ([ASH 2021 poster \(wmda.info\)](#)), 2021
  - <sup>12</sup> Result from Survey 'Registry operations during a pandemic – part 2', by WMDA 2020; question 11 and 15 (see appendix 2 and 3)
  - <sup>13</sup> Schuit M, Foeken L. D2.2 Resources for registry operations for import/export to EU Member States. 2020 SAVDON, WP1 Grant Agreement number 881553.
  - <sup>14</sup> WMDA Share page: Registry policies on vaccine programs/requirements and policies for donors (<https://share.wmda.info/x/c5GtFQ>)